about
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDSVitamin A supplementation for reducing the risk of mother-to-child transmission of HIV infectionMale circumcision for prevention of homosexual acquisition of HIV in menA combination drug of abacavir-lamivudine-zidovudine (Trizivir®) for treating HIV infection and AIDSVaginal disinfection for preventing mother-to-child transmission of HIV infectionVitamin A supplementation for reducing the risk of mother-to-child transmission of HIV infectionClinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registryThe impact of mass media interventions on tuberculosis awareness, health-seeking behaviour and health service utilisation: a systematic review protocol.Genetic variation in TLR genes in Ugandan and South African populations and comparison with HapMap dataA systematic review of randomized controlled trials of prenatal and postnatal vitamin A supplementation of HIV-infected women.The role of dendritic cells in driving genital tract inflammation and HIV transmission risk: are there opportunities to intervene?Maturation of innate responses to mycobacteria over the first nine months of life.Association of human TLR1 and TLR6 deficiency with altered immune responses to BCG vaccination in South African infants.Advances in childhood immunisation in South Africa: where to now? Programme managers' views and evidence from systematic reviews.Enhanced ex vivo stimulation of Mycobacterium tuberculosis-specific T cells in human immunodeficiency virus-infected persons via antigen delivery by the Bordetella pertussis adenylate cyclase vector.Modulation of Female Genital Tract-Derived Dendritic Cell Migration and Activation in Response to Inflammatory Cytokines and Toll-Like Receptor AgonistsLower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive.Vaginal microbicides for preventing mother-to-child transmission of HIV infection--no evidence of an effect or evidence of no effect?The SIGLEC14 null allele is associated with Mycobacterium tuberculosis- and BCG-induced clinical and immunologic outcomes.Vitamin A supplements for reducing mother-to-child HIV transmission.A Functional Toll-Interacting Protein Variant Is Associated with Bacillus Calmette-Guérin-Specific Immune Responses and Tuberculosis.Optimization of a whole blood intracellular cytokine assay for measuring innate cell responses to mycobacteria.Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans.Migration and measles.Cochrane Column.Contribution of APCs to mucosal-associated invariant T cell activation in infectious disease and cancer.Lessons and myths in the HIV/AIDS responseEradication of poliomyelitisToll-like receptor chaperone HSP90B1 and the immune response to MycobacteriaSystematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosisClinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort studyImmunogenicity and safety of fractional dose yellow fever vaccination: A systematic review and meta-analysisEarly antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosisIntervening along the spectrum of tuberculosis: meeting report from the World TB Day nanosymposium in the Institute of Infectious Disease and Molecular Medicine at the University of Cape Town
P50
Q24200188-1718D801-F32D-48BC-B932-E8DC8B282375Q24234927-4DF2E338-D63D-42FB-8E74-F9EC116DC464Q24236267-722756F0-2DE9-4474-B52D-4BCA3477F57EQ24239831-9CE828F3-1055-4776-BC9B-F80BDAC596B3Q24245463-13F05347-D8BB-4759-80EC-D1B3B64DDE6DQ24245896-1944FFB4-9AB9-4B57-9A84-79AC9A63C046Q25257355-A360EE3A-62B6-4444-9EFD-66D3DFB87D2AQ26829087-5A2F46EA-6765-4789-8535-1389C3BD8C9EQ30575475-8499AD6E-D55C-4007-95EB-2523E67B0FE5Q33377311-182229FE-2C6C-4514-82BA-67F300A04E29Q33662836-F3D1B0CB-2B23-4382-869A-0423470258B8Q33723428-CFB19347-0AA0-4C3B-9AAE-265E9F761BB4Q33996621-8EFEBF68-A542-4E18-B323-E8927F44D1D5Q34360356-350D4A75-0A61-46B8-BF3A-AACC598F27A8Q35946908-C7F96942-D47B-47BA-9F53-725B222D6109Q36015881-E0CCA79C-8B96-4AB3-A9B2-0FAC72D9067AQ36654106-8E289723-95E8-4401-B204-61F40423BB15Q36931656-B48AD2AB-0FE1-439F-A9A5-573459F2D1C6Q39031528-E5DF73F7-5EBC-4ACD-A24F-0C09CF510C0EQ40053700-F35C84D7-BEC0-4B02-AB76-617973E7DFEFQ40229934-41594127-B12B-4D52-99E2-84145A4478E2Q40892177-BE83456D-36AD-495E-AE23-6227713F3287Q46168249-2529F8C8-C8E2-4590-8D12-98C94DD0840DQ46534404-449FFF15-77B6-42E6-9E69-21730F838272Q46889146-AD02BFDA-C5C4-4E15-B839-E7C8BA2D6962Q52598286-FCF33A2A-BAF0-42F5-B274-BCA92980F78CQ59149348-7E329FCE-B3A3-42B7-BE0B-B8A6A82D7B00Q59149353-FCE7EF93-BB08-4EE7-B2C5-4CD143EFCC39Q60302244-1FB51911-18C8-4EC9-A307-F7C34068816CQ90752630-A4D2E415-2CCA-4D78-9CA8-B035BA1FD703Q91650621-F96EA09A-1D85-4558-A383-70E371A05E6AQ92142515-568F1840-9943-4A99-8DB3-E1892F79EDD7Q92486406-EE615790-92FD-4E35-8D0B-F59E2D899722Q96026654-F0E1B21A-EEBB-4883-B2A9-0B8C71E3E989
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Muki Shey
@ast
Muki Shey
@en
Muki Shey
@es
Muki Shey
@nl
Muki Shey
@sl
type
label
Muki Shey
@ast
Muki Shey
@en
Muki Shey
@es
Muki Shey
@nl
Muki Shey
@sl
prefLabel
Muki Shey
@ast
Muki Shey
@en
Muki Shey
@es
Muki Shey
@nl
Muki Shey
@sl
P106
P108
P21
P31
P496
0000-0002-8776-4737